CMPX vs. PCB, ELEV, XFOR, ABOS, IPHA, OPT, CRDF, KOD, IPSC, and PSTX
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Elevation Oncology (ELEV), X4 Pharmaceuticals (XFOR), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), Opthea (OPT), Cardiff Oncology (CRDF), Kodiak Sciences (KOD), Century Therapeutics (IPSC), and Poseida Therapeutics (PSTX).
Compass Therapeutics (NASDAQ:CMPX) and PCB Bancorp (NASDAQ:PCB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
In the previous week, PCB Bancorp had 1 more articles in the media than Compass Therapeutics. MarketBeat recorded 1 mentions for PCB Bancorp and 0 mentions for Compass Therapeutics. PCB Bancorp's average media sentiment score of 0.60 beat Compass Therapeutics' score of 0.00 indicating that PCB Bancorp is being referred to more favorably in the news media.
PCB Bancorp has a net margin of 18.97% compared to Compass Therapeutics' net margin of 0.00%. PCB Bancorp's return on equity of 11.25% beat Compass Therapeutics' return on equity.
PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks.
68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 33.0% of PCB Bancorp shares are owned by institutional investors. 30.0% of Compass Therapeutics shares are owned by company insiders. Comparatively, 25.0% of PCB Bancorp shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Compass Therapeutics received 11 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 71.88% of users gave Compass Therapeutics an outperform vote while only 50.00% of users gave PCB Bancorp an outperform vote.
Compass Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 540.57%. Given Compass Therapeutics' higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than PCB Bancorp.
Compass Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, PCB Bancorp has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Summary
PCB Bancorp beats Compass Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
